Intellia reports positive Phase 3 results for hereditary angioedema treatment

June 13, 2026 7:30 AM

Intellia Therapeutics Inc. (NASDAQ: NTLA) presented additional positive results from its Phase 3 HAELO clinical trial of lonvoguran ziclumeran for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found